TOFARACE
MRP: 4,150
Packaging: 10x1x10
Pack Type: tablet
Composition:
Tofacitinib 5mg
Indication:
Rheumatoid Arthritis, Psoriatic Arthritis, Ulcerative Colitis
Description:
Tofacitinib 5mg is an oral Janus Kinase (JAK) inhibitor used in the management of moderate to severe autoimmune conditions. It provides targeted immunomodulation by selectively inhibiting JAK enzymes involved in inflammatory signaling pathways. Tofacitinib is commonly prescribed in rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis to reduce inflammation, improve joint mobility, and manage systemic symptoms.
Tags:
- Reduces joint pain, swelling, and stiffness
- Improves mobility and quality of life
- Oral administration (no injections required)
- Effective in patients unresponsive to conventional DMARDs
- Rapid onset of action (visible improvement in 2–4 weeks)
Usage Information
Dosage
Standard Dose: Rheumatoid/Psoriatic Arthritis: 5 mg twice daily Ulcerative Colitis: 10 mg twice daily for induction, then 5 mg twice daily maintenance Route: Oral With or without food Dosage adjustments may be required in renal/hepatic impairment
Side Effects
Common: Headache, diarrhea, increased cholesterol, nasopharyngitis Serious: Infections (herpes zoster, TB), liver enzyme elevation, anemia or neutropenia, risk of thrombosis Requires routine CBC, LFT, lipid profile
Contraindications
Active infections (TB, hepatitis, etc.) Severe liver impairment Pregnant or breastfeeding women History of blood clots or cardiovascular disease Concurrent use with other strong immunosuppressants (e.g., azathioprine, cyclosporine)
Availability
Tofacitinib 5mg tablet uses JAK inhibitor for rheumatoid arthritis Tofacitinib for ulcerative colitis Tofacitinib immunosuppressant medicine Autoimmune disease oral treatment Tofacitinib side effects and dosage